US 11,753,445 B2
Therapeutic peptides
Kenneth Cundy, Atherton, CA (US); Remi Magnan, Sunnyvale, CA (US); Kent K. Grindstaff, San Jose, CA (US); Wendy Luo, Sunnyvale, CA (US); Yongjin Yao, Santa Clara, CA (US); and Liang Zeng Yan, Carmel, IN (US)
Assigned to COHBAR, INC., Menlo Park, CA (US)
Filed by COHBAR, INC., Menlo Park, CA (US)
Filed on Apr. 11, 2022, as Appl. No. 17/717,982.
Application 17/717,982 is a continuation of application No. 17/393,944, filed on Aug. 4, 2021, granted, now 11,332,497.
Application 17/393,944 is a continuation of application No. 16/336,089, granted, now 11,111,271, previously published as PCT/US2017/053597, filed on Sep. 27, 2017.
Claims priority of provisional application 62/401,123, filed on Sep. 28, 2016.
Prior Publication US 2022/0242912 A1, Aug. 4, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 7/08 (2006.01); A61K 38/00 (2006.01); A61P 1/16 (2006.01); A61P 3/04 (2006.01); C07K 7/06 (2006.01); C07K 14/47 (2006.01)
CPC C07K 7/08 (2013.01) [A61P 1/16 (2018.01); A61P 3/04 (2018.01); C07K 7/06 (2013.01); C07K 14/47 (2013.01); A61K 38/00 (2013.01)] 31 Claims
 
1. A method of decreasing liver triglycerides, alanine aminotransferase (ALT), or aspartate aminotransferase (AST) in a subject with abnormal elevated liver triglycerides, ALT, or AST, the method comprising administering to the subject, in an amount effective to decrease liver triglycerides, ALT, or AST, a composition comprising a peptide and a carrier, excipient, or diluent,
the peptide comprising the amino acid sequence of formula I:
 
 (I)
 
 (SEQ ID NO: 1)
 
 X1-QE-X2-X3-YI-X4-Y-X5-R-X6
wherein:
X1 is absent or if present is X7-RW, wherein X7 is absent or if present is M or E;
X2 is M, A or E;
X3 is G, N or Q;
X4 is F or A;
X5 is P or A;
X6 is absent or if present is KL-X8 or X9-LR, wherein X8 is absent or if present is R or A and X9 is selected from K, A, (dA), N and 0;
wherein the amino acid sequence of formula I is selected from the group consisting of:
 
 (SEQ ID NO: 11)
 
 MRWQEAGYIFYPRKLR;
 
 
 (SEQ ID NO: 149)
 
 MRWQEMGYIFYPR(dA)LR;
 
 
 (SEQ ID NO: 208)
 
 MRWQEMNYIFYPR;
 
 
 (SEQ ID NO: 213)
 
 MRWQEMGYIFYPRNLR;
 
 
 (SEQ ID NO: 219)
 
 MRWQEMQYIFYPRALR;
 
 
 (SEQ ID NO: 248)
 
 RWQEMNYIFYPR;
 
 
 (SEQ ID NO: 19)
 
 MRWQEMGYIFYPRALR;
 
 
 (SEQ ID NO: 21)
 
 MRWQEMGYIFYPRKLA;
 
 
 (SEQ ID NO: 17)
 
 MRWQEMGYIFYARKLR;
 
 
 (SEQ ID NO: 217)
 
 RWQEMGYIFYPRQLR;
 
 
 (SEQ ID NO: 172)
 
 MRWQEEGYIFYPRKLR;
 
 
 (SEQ ID NO: 241)
 
 ERWQEAGYIAYPR;
 
 and
 
 
 (SEQ ID NO: 211)
 
 RWQEMQYIFYPR;
or a C-terminal acid or amide, or an N-acetyl derivative thereof; or a pharmaceutically acceptable salt thereof.